Poster Sessions
Poster Presentations - Monday Afternoon
2:00 p.m. - 4:30 p.m.
Categories: Critical Care, Drug Information, Drug-Use Evaluation, Herbals /Alternative Medicines, Infectious Diseases, Oncology
Special
Board 1 Emerging roles in public health: a challenge for health-system pharmacists, Vaiyapuri Subramaniam, John Quinn, Ruth Nemire, Frank Pucino, Ceressa Ward, Ashok Ramalingam, Robert Dombrowski, Karim Calis (P1)
Critical Care
Board 2 Analysis of the effect of calculated two hour frequency for glucose determinations on hypoglycemia incidence using computer software for tight glucose control (TGC), Robert A. Rittase, Debra A. Miller, Thomas A. Martin, William Patrick Burgess (P2D)
Board 3 Colchicine toxicity: the need for a specific antidote, Nancy Fagan, Mark Malesker, Lee E. Morrow, Robert Wear, Dan Schuller (P3E)
Board 4 Decentralized pharmacy services for a level II trauma and intensive care program, Tracey Okabe-Yamamura, Kevin Okuni, Sibusisiwe Gumbo, Jim Walsh (P4D)
Board 5 Development of an alcohol withdrawal protocol, Diane M. McClaskey, Mark Carlson, Daniel Sontheimer (P5E)
Board 6 Evaluation of esmolol-related extravasation, Tammy L. Burns, Debra L. Lee, Greg Peitz, Mark Malesker, Lee E. Morrow, Karl Samuelson, Jodi Volkens (P6E)
Board 7 False-positive phencyclidine immunoassay caused by venlafaxine, Tammy L. Burns, Lee E. Morrow, Mark Malesker, Paul L. Price, Debra L. Lee (P7E)
Board 8 Fatal case of metformin self-overdose, Tammy L. Burns, Kiran Lassi, Tammy Wichman, Mark Malesker, Debra L. Lee (P8E)
Board 9 How common are drug incompatibilities in an Intensive Care Unit (ICU)?, Jeffrey T. Thiel, Philip Schneider, Craig Pedersen, Jaclyn LeBlanc, Katherine Bellebaum, Joseph Dasta (P9D)
Board 10 Implementation of a safe and effective insulin infusion protocol in a critical care unit, Monte L. Roemmich, Joan L. Viets, Julie M. Bubach (P10D)
Board 11 Implementation of an insulin infusion protocol, Aaron Rosenbloom (P11E)
Board 12 Implementation of strategies to improve the incidence of ventilator associated pneumonia, Julie M. Bubach, Christy Martin, Amy Aeilts (P12D)
Board 13 Intermittent metoprolol infusion as an alternative to esmolol, Anthony E. Zimmermann (P13E)
Board 14 Intravenous insulin infusion transition to subcutaneous basal insulin: a pharmacist directed protocol improves transfer delays out of the cardiovascular intensive care unit, Kristine K. Gullickson, Christina Askew, Sue Sendelbach, William Dickey, Robert Miner (P14D)
Board 15 Nursing satisfaction survey concerning tight glycemic control protocols in the ICU, Pamela A. Foral, Mark Malesker, Daniel E. Hilleman, Keith Christensen, Ann McPhillips (P15E)
Board 16 Preparing staff pharmacists for intensive care rounds: a pharmacotherapeutic tool for managing patient care, Carol N. Carson (P16D)
Board 17 The role of platelet mapping in clopidogrel therapy: A retrospective evaluation, Benjamin Johnson (P17R)
Board 18 Safety of oral naloxone for the reversal of opiate induced constipation in the intensive care unit, Paul A. Arpino, Laurin M. Flynn (P18R)
Drug Information
Board 19 Assessing the current job responsibilities and training of drug information specialists: a national survey, Jacob P. Gettig, Joseph K. Jordan, Amy H. Sheehan (P19E)
Board 20 Development and evaluation of the injection ordering system by the Microsoft Access, Takeshi Onodera, Yukiko Chida (P20D)
Board 21 Development and implementation of guidelines for the management of extravasation of non-cytotoxic agents, Shelby L. Corman, Margaret M. Verrico (P21D)
Board 22 The development of a biologic information website for healthcare professionals, Fiona Kelly, Bernard Joseph Carr, Veronica Treacy, Roisin Adams (P22D)
Board 23 Dosage adjustment and monitoring the side effects of the anticancer drug in Tokushima University Dental Hospital, Yasushi Kirino, Toshimi Nakamura, Hirotaka Nishisako, Natsuko Ise, Keisuke Ishizawa, Toshihide Kujime, Kazuhiko Teraoka, Kazuyoshi Kawazoe, Kazuo Minakuchi (P23D)
Board 24 Effect of a web-based continuing education program on pharmacist learning, Burgunda V. Sweet, Lynda S. Welage (P24D)
Board 25 Effects of eszopiclone on various drug screens, Carolyn Soo, Gary Maier, John Karafilidis, Robert Rubens, Raymond Claus, James Roach (P25E)
Board 26 Efficiency of Google Scholar in locating primary literature to answer drug-related questions, Maisha Kelly Freeman, Stacy A. Lauderdale, Michael G. Kendrach (P26D)
Board 27 Enhancing awareness of drug safety through an internship in pharmacoepidemiology, Bao-Anh Nguyen-Khoa, Judith K. Jones (P27D)
Board 28 Impact of incorporating team-based learning in an academic setting, John Redwanski, Alexander Wilson (P28D)
Board 29 Implementation of a new pharmacy and therapeutics committee structure in a large academic institution, Morton P. Goldman, Mandy C. Leonard, David A. Kvancz, Frank Michota, Jr. (P29D)
Board 30 Palonosetron's clinical differentiation may be explained by new molecular pharmacology research., Camilo Rojas, Marigo Stathis, Ajit Thomas, Ed Massuda, Jesse Alt, Jie Zhang, Ed Rubenstein, Silvia Sebastiani, Sergio Cantoreggi, Barbara Slusher (P30D)
Board 31 Practice makes perfect: increasing students' confidence and skills in searching the literature, Vicki R. Kee, Kimberly Bloedel, Vernon K. Duba, Jeffrey C. Reist (P31D)
Drug-Use Evaluation
Board 32 Adherence to formulary restrictions criteria for palperidone therapy in schizophrenia and schizoaffective disorders after failure on risperidone and another atypical antipsychotic agent., Andrea C. Henry, Alphonsus Okpara, Angie E. Maxwell (P32D)
Board 33 Antibiotic treatments duration : evaluation in a geriatric hospital, Juliette Raffin, Isabelle Peyron, Nadine Oboa, Salah Gallah, Anna Sarfati (P33E)
Board 34 Appropriate inpatient usage of fosphenytoin, Michael Nyame-Mireku, Susan Cogut (P34E)
Board 35 Appropriate inpatient usage of intravenous levetiracetam, Michael Nyame-Mireku, Jessica Peterson, Noeil Luther, Timir Mehta, Scott Vaughan (P35E)
Board 36 Assessment of barriers to medication adherence in patients with diabetes using the ASK-20 in a clinic community pharmacy setting, Denise M. Martinez, Shenita A. Outland, J. David Hayes, Cathyrn C. Salinas, Jinhee X Park, Elizabeth P. Skinner, Gary K. Rice (P36R)
Board 37 Budgetary impact using quetiapine fumarate for unapproved indications in a state wide correctional health system, John A. Hedge (P37E)
Board 38 Can telepharmacy technology improve medication compliance in patients who are uninsured?, Timothy R. Hudd, Diane Gatchell, David Barry, Joseph Ferullo, Gary Tataronis (P38R)
Board 39 Cardiovascular accidents in patients at cardiovascular risk without antithrombotic prophylaxis, Covadonga Perez, Maria Muñoz, Eva Delgado, Ana Alvarez, Esther Gómez de Salazar, Teresa Bermejo (P39D)
Board 40 The clinical and economic impact of guidelines implementation on darbepoetin usage in a community hospital, George Z. Shehata, Mona Philips (P40E)
Board 41 Clinical pharmacists improve heart failure in patients with secondary prevention medication compliance research, Lingyan Jian (P41E)
Board 42 Comparative erythropoietic response between epoetin alfa and darbepoetin alfa in the inpatient hemodialysis unit at Wake Forest University Baptist Medical Center (WFUBMC), Dwayne A. Pierce, Regina H. Schomberg, John C. Williamson (P42E)
Board 43 Comparison of adverse effects between dexmedetomidine and propofol in the post-operative setting, Katharine A. Sheldon, Anthony Gerlach (P43E)
Board 44 Comparison the effect of the cyclosporine and tacrolimus on the health-related quality of life in kidney transplantation patients, Shiting Liu, Qing Zhang, Yi Qian (P44E)
Board 45 Compassionate use of mycophenolic acid., Maria Lacal, Ana G. Moya, Rebeca F. Aldaz, Ana W. Valladolid, Vanessa Castro (P45E)
Board 46 Conducting quality practice research project on a day-to-day basis: evaluation of IGIV use in clinical practice, Alberto Frutos Perez-Surio, Elena Tomas Guillen, Ferran Sala Piñol, Miriam Maroto Hernando, Julio Martinez Cutillas, Josep Monterde Junyent (P46R)
Board 47 Contrasting case-mix characteristics of patients treated with niacin extended release and fenofibrate in a large managed care dataset, Woodie M. Zachry, Eddilisa Martin, Andrea R. Hume (P47E)
Board 48 Differences in sustained virological response between peginterferon alfa-2a and alfa-2b in chronic hepatitis C infection, Montserrat Masip, Núria Rudi, Mercedes Vergara, Marta Gallach, Alba Cebollero, Antoni Gavarró (P48E)
Board 49 Digitized management of hospital pharmacy, Aiqin Zhang (P49D)
Board 50 Drug Utilization Evaluation Using 12 and 36 Month Pre-Index Periods in a Cohort of Fluticasone Propionate/Salmeterol Users, Richard H. Stanford, David Stempel, Manabu Akazawa (P50D)
Board 51 Drug-use evaluative study of Abciximab in a Spanish Hospital, Ana G. Moya, Rebeca F. Aldaz, Cristina G. Garcia, Ana W. Valladolid, Isabel G. Acebal (P51E)
Board 52 Evalaution for use of aprepitant for post-operative nausea and vomiting, Tracey Okabe-Yamamura, Jim Walsh (P52D)
Board 53 Evaluation of a cost savings initiative: switching patients from Atorvastatin to Simvastatin, Jessica L. Bowen, Angela Aldrich (P53)
Board 54 Evaluation of linezolid utilization at an academic medical center, Kelli Stadalman, Charles James, Robert Schoenhaus, Farivar Jahansouz, Peter Fedullo (P54E)
Board 55 Evaluation of proton pump inhibitor (PPI) initiation and continuation post-discharge in hospitalized patients admitted to family medicine service, Courtney I. Jarvis, Michele Matthews (P55R)
Board 56 Evaluation of the effectiveness of a "restricted use" order form for appropriate usage of intravenous proton pump inhibitors at an academic medical center. , Michael W. Daly, Scott Micek (P56E)
Board 57 Evaluation of the utilization of direct thrombin inhibitors for the management of heparin-induced thrombocytopenia in a community hospital, Nancy L. Delgadillo, Cary Machado, Heidi Clarke, Marcus Droege, Gloria Kelly (P57E)
Board 58 Evaluation of use of antidotes in changi general hospital (CGH): flumazenil, naloxone and protamine sulphate, Serene Yeow, Jonathan Seah, Jing Jing Wong (P58E)
Board 59 Gemfibrozil versus fenofibrate in the treatment of dyslipidemia in a veteran population, Sonia Nonomme, Patricia Fernandez-Quevedo, Carmela Jean (P59E)
Board 60 Generic antiretroviral drug approvals: reduction of median approval times and impact on public health, Beth F. Fritsch, Devvrat Patel, Paul Seo, Connie Jung, Barbara Davit (P60D)
Board 61 Glycemic control using a newly implemented insulin protocol in non-intensive care unit (ICU) patients, Sheila Marie Paguyo, Michael Katz, Marie Maloney, John Glover (P61E)
Board 62 Implementation and impact of venous thromboembolic risk assessment and prophylaxis order set for surgical patients, Rebecca A. Lines, Kate Farthing (P62E)
Board 63 Infliximab for hidradenitis suppurativa, Beatriz B Sordo, Mikel Castaño, Laura Lombera, Unai Gonzalez, MariaPuy Figuero (P63R)
Board 64 Ketorolac use in a pediatric population, Robyn S. Bonner, Stephen K. Hetey, Hui Kang (P64E)
Board 65 Long-Term use of benzodiazepine receptor agonists, Justin Doan, Robert W. Baran (P65E)
Board 66 Measuring optimal nesiritide therapy through a medication use evaluation, Patrick S. Monroe (P66E)
Board 67 PACE and Medicare Part D: an examination of formularies, cost sharing and prior authorization, Annesha White, Allyson Hall (P67R)
Board 68 Pharmacoeconomic impact of ropivacaine and fentanyl epidurals, Cindy Nettle (P68E)
Board 69 Pharmacy managed heparin protocol with anti-factor Xa levels, Alicia Juska, Zoon Park, Ramesh Patel (P69R)
Board 70 Process to improve recombinant tissue plasminogen activator (rtPA) access for acute ischemic stroke patients in the emergency department: a retrospective review, Lorrie L. Burns, Charles F. McCluskey, Jeanette Ripley (P70R)
Board 71 Racemic albuterol and levalbuterol treatment trends, David J. Lee (P71E)
Board 72 Rapid detection of the polymorphisms of cytochrome P450 (CYP) 2C9 and the vitamin K oxide reductase complex submit 1 (VKORC1) genes for the warfarin dose adjustment by SMart-Amplification Prosess., Tohru Aomori, Koujirou Yamamoto, Yukiyoshi Fujita, Kyoko Obayashi, Katsunori Nakamura, Masahiko Kurabayashi, Yasumasa Mitani, Yuki Kawai, Atsuko Oguchi-Katayama, Yoshihide Hayashizaki, Ryuya Horiuchi (P72E)
Board 73 Recombinant human erythropoietin and anemia of prematurity, Monike De Miguel, MariaPuy Figuero, Mikel Castaño, Laura Lombera, Mariangeles Gil (P73D)
Board 74 Replacing gemfibrozil with fenofibrate in patients on statins: efficacy and safety outcomes, Claudia N. Swenson, Greg Stahly (P74E)
Board 75 Retrospective analysis of the frequency of prescribing stress ulcer prophylaxis in a general internal medicine population, Andrea L. Fumi, Jason Jackson, Ann Scates, Joanne Latour (P75E)
Board 76 Retrospective evaluation of efficacy and safety of lepirudin for the treatment of suspected heparin induced thrombocytopenia, Karen M. Frock, Jennifer A. Sullivan (P76E)
Board 77 Short-term use of smoking cessation products as nicotine replacement in ambulatory surgery patients, Joyce M. Juracek, Dorraine Reynolds, Shanna Stofer, Lorry Page (P77R)
Board 78 Stress ulcer prophylaxis pattern in Lebanon: is it appropriate?, Abeer A. Zeitoun, Marwan Akel, Khodor Faour, Hani Dimassi (P78E)
Board 79 Use of recombinant factor seven in non hemophilia adult and pediatric patients during and post cardiac surgery, Valerie Shenefelt, Sarah Johnson, Amy Becker, Jeff Vande Berg (P79E)
Herbals /Alternative Medicines
Board 80 Hypouricemic effect and regulatory effects on autonomic function of Shao-Yao Gan-Cao Tang, a Chinese herbal prescription, in asymptomatic hyperuricemic vegetarians, Lih-Chi Chen, Tsung-Hsiu Wu (P80E)
Board 81 Pharmacist teaching in cardiac rehab: why is red rice yeast extract all the patients want to talk about?, Susan M. Mashni, William Wesley Carroll (P81D)
Infectious Diseases
Board 82 Acinetobacter resistance in the United States: in vitro evaluation of tigecycline and comparators against recent isolates, Brian Johnson, Brian Johnson, Sam Bouchillon, Robert Badal, Meredith Hackel, Daryl Hoban, Michael Dowzicky, Jack Johnson (P82E)
Board 83 Antibiogram development, update and clinical application: a pharmacy-driven core clinical initiative across multiple hospitals and health systems, Rabiah T. Dys, Valerie Castellani Sheehan (P83E)
Board 84 Chronic suppressive antibiotic therapy for recurrent enterococcal bacteremia: a case report, Jamie Winner, David Wagner, Mark Beilke (P84E)
Board 85 Comparative in vitro activity of topical wound care products against community-associated methicillin resistant Staphylococcus aureus, David T. Bearden, George P. Allen, J. Mark Christensen (P85E)
Board 86 Comparison of nephrotoxicity in patients receiving tenofovir-containing highly active anti-retroviral therapy (HAART) versus tenofovir-naive HAART, Amber C. Fullmer, Noreen Chan-Tompkins, David Piontkowsky (P86E)
Board 87 Comparison of susceptibilities to Pseudomonas aeruginosa (PSA) in respiratory, blood and wound infections from a multi-institution database in 2005-2006., Vikas Gupta, Stephen Brossette, R.S. Johannes, Kathakali Ghosh, Lien Vo, Jeff Schein, Andrew F. Shorr, Marin H. Kollef (P87E)
Board 88 Compatibility of doripenem injection with selected other drugs during simulated y-site co-administration, Lawrence A. Trissel, Matthew K. Brammer, Pak Chan, Kathy Heatherly, Craig Trusley, Thomas Kupiec, Petros A. Psathas, Daniel E. Schaufelberger, Timothy P. Gilmor (P88E)
Board 89 Daptomycin (DAP) use as outpatient antibiotic therapy (OPAT), Jack Brown, Kenneth Lamp (P89E)
Board 90 Development and implementation of an antibiotic stewardship program, Nickie D. Greer, William Sutker (P90E)
Board 91 Development of a Polymixin Dosing tool for treatment of Resistant Klebsiella pneumoniae, Kevin P. McDonough (P91D)
Board 92 Development of a unit-specific emergency department antibiogram, Esty Trimino, Janelle Berg (P92D)
Board 93 Documentation of history of Clostridium difficile (C. difficile) to minimize recurrence, Shaindy Gluck (P93R)
Board 94 Economic burden of community or health care associated candidemia and other blood stream infection: multivariate analysis of length of stay and cost, James Spalding, Andrew F. Shorr, Xiaowu Sun, Vikas Gupta, Ed Cox, Ying Tabak (P94E)
Board 95 Effect of removal of duplicate isolates on an antibiogram (ABGM) at a tertiary hospital, Antonia Zapantis, Holly E. Balcer, William Fagan (P95E)
Board 96 Effectiveness of a soft restriction policy for broad-spectrum antibiotics in a community-based teaching hospital, Deirdre B. Minihan, Nichole Clemons, Jeffrey Nemeth, Julia White (P96D)
Board 97 Epidemiologic investigation of outbreak of Serratia marcescens urinary tract infection in intensive care unit, Hyekyung Kang, Sunjoo Kim (P97E)
Board 98 Evaluating the appropriate prescribing of antibiotics in the treatment of community acquired MRSA versus hospital acquired MRSA infections in a community hospital, Frances A. Ordieres, Yilian Alonso, Jonathan D. Hoffman (P98R)
Board 99 Evaluating the treatment of MRSA infections in a community hospital setting, Frances A. Ordieres, Mary Alvarez, Yilian Alonso, Jonathan D. Hoffman (P99R)
Board 100 Evaluation of a standardized vancomycin nomogram in computerized physician order entry system, Lauren Keyser, Amy Pakyz, Kimberly Lee (P100D)
Board 101 Evaluation of antimicrobial use and resistance in the intensive care units utilized defined daily dose (DDD), Vanthida Huang, Nadia Z. Haque, Marcus J. Zervos (P101E)
Board 102 Evaluation of the incidence, risk factors, and treatment of Clostridium difficile-associated diarrhea (CDAD) in a community hospital, Holly E. Balcer, Cary Machado, Olga Bendyk, Gloria Kelly, Marcus Droege (P102E)
Board 103 Evaluation of tigecycline against multi-drug resistant (MDR) Streptococcus pneumoniae in the United States, Brian Johnson, Brian Johnson, Sam Bouchillon, Robert Badal, Meredith Hackel, Daryl Hoban, Michael Dowzicky, Jack Johnson (P103E)
Board 104 Evaluation of tigecycline utilization in a university teaching hospital, Jennifer Cupo Abbott, Jiwon Kim, Sean Han Koh (P104E)
Board 105 Hospital length of stay and total hospital costs in patients with imipenem-resistant Pseudomonas aeruginosa in respiratory, wound and blood isolates from a multi-institution database in 2005-2006., Vikas Gupta, Stephen Brossette, R.S. Johannes, Kathakali Ghosh, Jeff Schein, Lien Vo, Andrew F. Shorr, Marin H. Kollef (P105E)
Board 106 Identifying heterogenous gram-negative isolate resistance to imipenem in Florida hospitals: results of the antimicrobial resistance management (ARM) program, John G. Gums (P106D)
Board 107 Impact of pharmacist intervention on compliance with surgical care improvement project (SCIP) guideline for duration of antimicrobial prophylaxis, Nancy M. Wyatt, Joke Fasoranti (P107R)
Board 108 Implementation of a computerized physician order entry (CPOE)-based protocol to improve the care of patients with community-acquired pneumonia, Robert Adamson, Phil Principe, Monica Shah (P108E)
Board 109 Implementation of a pharmacist managed infectious diseases program within the inpatient setting, Rani Dibbini, Dale Lieu, Jennigrace Bautista, Shawn Briere (P109D)
Board 110 Multidisciplinary approach to antibiotic streamlining: length of stay and cost savings evaluation., Corstiaan Brass, Yanina Magram, Kevin Mills (P110D)
Board 111 Outcomes assessment of a fluoroquinolone restriction program at a university hospital, Jenny Lam, Timothy Aaron Jones (P111E)
Board 112 Pharmacy interventions on antibiotic prescribing and its effect on the incidence of C. Difficile, Lyndall Vu, William Yee, Katherine Lee (P112D)
Board 113 Recurrence of skin infections in patients treated with telavancin versus vancomycin for complicated skin and skin tissue infections in a New Orleans emergency department., Lala Mathers Dunbar, Deborah Thurston Sibley, John Hunt, Steven Barriere, Michael Kitt, Juan David Ramirez, Sharon Weintraub, Alan Marr, Ahmad Shateri-Mirabadi, Hilary Thompson (P113E)
Board 114 Retrospective analysis of methicillin-resistant Staphylococcus aureus (MRSA) isolates in a tertiary hospital, Antonia Zapantis, Kerry Ann Peters, Robert J Kraljevich (P114E)
Board 115 Risk factors associated with Clostridium difficile infection in the ICU's of a community teaching hospital, Salwa Elarabi, Patricia Masters (P115R)
Board 116 Risk modifiers associated with Clostridium difficile infection in the ICU's of a community teaching hospital, Salwa Elarabi, Patricia Masters (P116R)
Board 117 Surveillance of antibiotic use in Dutch hospitals: 2001-2005, Anouk D. Lindemans, Laureen A. Lammers, Pieternella M.G. Filius (P117D)
Board 118 Total and departmental costs and length of stay in hospitalized community-acquired pneumonia (CAP) patients for two respiratory quinolones: levofloxacin and moxifloxacin, Vanja Sikirica, Carmela Janagap, Richard Grant, William Crown, William Olson, Jeff Schein (P118E)
Board 119 Treatment of methicillin-resistant Staphylococcus aureus (MRSA) exacerbations in cystic fibrosis (CF) patients: a retrospective review, Celeste Rudisill, Brandon Bookstaver, Caroline Litchfield, David Brown, III, Daniel Brown (P119R)
Board 120 Trends in Clostridium difficile-associated diarrhea, Nika Sajed, Charles James, Theodore Katsivas, Francesca Torriani, Robert Schoenhaus, Russell Luke (P120E)
Board 121 Trends in nosocomial Clostridium difficile-associated diarrhea (N-CDAD), Charles James, Nika Sajed, Theodore Katsivas, Russell Luke, Francesca Torriani, Robert Schoenhaus (P121E)
Board 122 Vancomycin: A retrospective evaluation of clinical outcomes and MIC for MRSA bacteremia in a critical care unit, Angela M. Harding, Tara Fisher, Joseph Gastaldo (P122R)
Oncology
Board 123 Adverse events observed in the chemotherapy regimens for the colorectal cancer treatment, Eva Fernández, Susana Redondo, Cesar Salort, Rosa Garriga, Ramón Pla, Ma Angeles Parada, Albert Planas, Mario Longoni, Magdalena Trullás (P123E)
Board 124 Assessment of oral mucositis among autologous hematopoietic stem cell transplant recipients receiving non total body irradiation containing regimens, Jill S. Bates, Ashley Morris Engemann, Lydia Mis (P124E)
Board 125 Assessment of venous thromboembolism (VTE) prophylaxis in oncology patients at a community hospital, Kelly K. Nystrom, Elizabeth L. Williams, Lynn A. Madsen, Christopher Destache, Estella M. Davis, Carla M. Christensen, Pamela A. Foral (P125E)
Board 126 Costs associated with disease progression among metastatic non-small cell lung cancer patients, Kathleen M. Fox, John Brooks, Jennifer Kim (P126E)
Board 127 Development of a bisphosphonate osteonecrosis risk reduction plan, Leslie Mader, Sara Griesbach (P127D)
Board 128 Development of oncology clinical pharmacist services in an outpatient academic cancer center, Sara K. Maier, Byron G. Peters (P128D)
Board 129 Evaluation of hydroxyurea prescribing in a large academic teaching hospital affiliated with a major cancer center, Daniel T. Voit, Anne McDonnell, Jorge O. Delgado-Flores, Karen Michaud, Joan Dang, Alka Vaidya, William Churchill, Sylvia Bartel (P129E)
Board 130 Evaluation of patient outcomes and costs associated with antiemetic regimens for chemotherapy-induced nausea and vomiting from a hospital perspective, Susan Weidner, Daniel B. Ng, Robert Miller (P130D)
Board 131 Genetic polymorphisms predictive of severe acute toxicities during chemotherapy for esophageal squamous cell carcinoma in Japanese, Hiroo Makimoto, Toshiyuki Sakaeda, Takao Tamura, Motohiro Yamamori, Ikuya Miki, Tatsuya Okuno, Naoko Cyayahara, Midori Hirai, Katsuhiko Okumura (P131E)
Board 132 Impact of a pharmacist developed, criteria-based evaluation designed to decrease inpatient administration of chemotherapy in an academic teaching hospital, David M. Baribeault, Bhavesh Shah, Radhika Sane, Keith Thomasset (P132D)
Board 133 Impact of a pharmacist-directed anemia management program on guideline adherence, Amanda Hafford, Niesha Griffith, Enrique Seoane-Vaquez, Sheryl Szeinbach (P133R)
Board 134 Impact of pharmacist intervention on the incidence of hand-foot syndrome of patients taking capecitabine, Jung Bo Kim, Young Ju Chun, Jung Tae Kim, Young Sook Lee, Sukhyang Lee (P134E)
Board 135 Incidence and management of hyperglycemia in a Bone Marrow Transplant Unit, Michael Steinberg, Jonathan Roberts (P135E)
Board 136 Maximizing patient safety in a medical oncology practice: a journey through failure mode effects analysis to computerized physician order entry., Don R. Janczak, Emily Robinson, Karol Huenerberg (P136E)
Board 137 Modifications chemotherapy treatment in patients with colorectal cancer, Eva Fernández, Susana Redondo, Cesar Salort, Albert Planas, Ramón Pla, Rosa Garriga, Mario Longoni, Magdalena Trullás (P137E)
Board 138 Outcomes of a hospital pharmacist run darbepoetin program post acquisition of multiple physician based outpatient oncology clinics, Emmanuel C. Markakis, Sam Genovese, Gary Dalin, Leslie Ley, Fran Reed (P138D)
Board 139 Panitumumab monotherapy in metastatic colorectal cancer patients intolerant to cetuximab, Mona Shing, Alan D. Langerak, Edith Mitchell, Puneet Cheema, George L. River (P139D)
Board 140 Panitumumab, a fully human monoclonal antibody against the epidermal growth factor receptor (EGFr): safety in patients with metastatic colorectal cancer (mCRC) across clinical trials., Marc Peeters, Eric Van Cutsem, Jordan Berlin, J. Randolph Hecht, Mona Shing, Rolando Ruiz, Michael Wolf, Rafael G. Amado (P140D)
Board 141 Pooled analysis of five clinical trials examining the predictive value of skin toxicity severity for response to panitumumab in patients with metastatic colorectal cancer (mCRC)., Teri Michelini, J. Randolph Hecht, Marc Peeters, Eric Van Cutsem, Rolando Ruiz, Michael Wolf, Rafael G. Amado, Jordan Berlin (P141D)
Board 142 Randomized, placebo-controlled trial evaluating aprepitant single dose plus palonosetron and dexamethasone for patients receiving highly emetogenic chemotherapy, Jon D. Herrington, Adam D. Jaskiewicz, Juhee Song (P142E)
Board 143 Skin lesions induced by bortezomib, Mariangeles Gil, Beatriz B. Sordo, Laura Lombera, Mikel Castaño, Monike De Miguel (P143D)
Board 144 Stability of busulfan injection prepared in 0.9 percent sodium chloride, Carina Verdier, Michael Anne Markiewicz (P144E)
Board 145 Statins in prostate cancer: is there a role?, Abeer A. Zeitoun, Houry Leblebjian, Maya Harajli, Shereen Nabhhani, Hani Dimassi (P145E)
Board 146 Visual disturbances caused by chemotherapy; innovative approaches in patient education to improve quality of life., Bruce Wong, Donald Chaplin, Susan Decristofaro, Mary Hanna, Thao Le, Steven Clark (P146E)